10th Annual Live Medical Crossfire®: Hematologic Malignancies

Overview

Physicians’ Education Resource^®, LLC, (PER^®) presents the 10th Annual Live Medical Crossfire^®: Hematologic Malignancies—a 2-day Medical Crossfire designed to interactively explore the most controversial clinical issues in the field of hematologic malignancies through live, interactive panel discussions with renowned experts. This meeting will contrast viewpoints of key opinion leaders across the country and world regarding emerging clinical data and current standards of practice across liquid tumors. Through this valuable discussion, health care professionals participating in this conference can better treat a broad range of patients with hematologic malignancies, understand current controversies, and more confidently personalize clinical decisions.

At the start of each Medical Crossfire segment, renowned experts across the field of hematology—from leukemias and lymphomas to myeloma—present a brief evidence-based assessment of current standards of practice and the most important, recent clinical trials to set the stage for each expert crossfire session. Sessions conclude with crossfire questions from the live audience. This innovative format provides the most practical and engaging educational forum available today in the field of hematologic malignancies.

This live Medical Crossfire: Hematologic Malignancies offers hematologists/oncologists who are involved in the care of patients with hematologic malignancies the opportunity to interact with leading faculty, build their base of clinical knowledge on new and emerging agents, maintain awareness of controversies in the field, and apply the best practices for the care of their patients to optimize outcomes.

Learning Objectives

• Evaluate the efficacy and safety of approved and emerging therapies based on current clinical trial data
• Select appropriate initial therapy using clinical evidence, guidelines, and patient- and disease-specific factors (including biomarkers)
• Develop longitudinal treatment strategies that incorporate sequencing across lines of therapy, prior treatment exposure, and anticipated next-line options
• Identify, monitor, and manage treatment-related adverse events across therapeutic classes
• Integrate multidisciplinary care strategies to further optimize the treatment of hematologic malignancies

Program Co-Chairs

Barbara Pro, MD; Saad Z. Usmani, MD, MBA, FACP, FASCO; Amer Zeidan, MBBS, MHS

To view full profile, click on the Program Co-Chairs tab above.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 10.5 Contact Hours.

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

European Board for Accreditation in Hematology (EBAH)

This activity has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of 10 CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.

Archive

Click below to view event overviews from previous years:

2025